Table 1 Patients’ characteristics.
Characteristics n (%) | Metformin | Insulin | Non-diabetes | P |
|---|---|---|---|---|
n = 312 | n = 79 | n = 3139 | ||
Age at diagnosis | 0.0001 | |||
≤ 55 years | 130 (41.7) | 28 (35.4) | 2113 (67.3) | |
> 55 years | 182 (58.3) | 51 (64.6) | 1026 (32.7) | |
BMI | 0.0001 | |||
< 25 | 110 (35.2) | 26 (32.9) | 1743 (55.5) | |
25–30 | 150 (48.1) | 39 (49.4) | 1143 (36.4) | |
≥ 30 | 52 (16.7) | 14 (17.7) | 253 (8.1) | |
Menopausal status | 0.0001 | |||
Pre | 145 (46.5) | 31 (39.2) | 2168 (69.1) | |
Post | 167 (53.5) | 48 (60.8) | 971 (30.9) | |
Tumour size | 0.0179 | |||
≤ 2 cm | 137 (43.9) | 29 (36.7) | 1499 (47.8) | |
> 2 cm, ≤ 5 cm | 134 (42.9) | 41 (51.9) | 1215 (38.7) | |
> 5 cm | 13 (4.2) | 5 (6.3) | 87 (2.8) | |
Uncertain | 28 (9.0) | 4 (5.1) | 338 (10.8) | |
Lymph node metastasis | 0.0038 | |||
0 | 200 (64.1) | 36 (45.6) | 1832 (58.4) | |
1–3 | 79 (25.3) | 25 (31.6) | 744 (23.7) | |
4–9 | 25 (8.0) | 11 (13.9) | 323 (10.3) | |
≥ 10 | 8 (2.6) | 7 (8.9) | 240 (7.6) | |
ER status | 0.5361 | |||
Positive | 244 (78.2) | 59 (74.7) | 2367 (75.4) | |
Negative | 67 (21.5) | 20 (25.3) | 760 (24.2) | |
Unknown | 1 (0.3) | 0 (0) | 12 (0.4) | |
PR status | 0.1507 | |||
Positive | 223 (71.5) | 56 (70.9) | 2084 (66.4) | |
Negative | 88 (28.2) | 23 (29.1) | 1043 (33.2) | |
Unknown | 1 (0.3) | 0 (0) | 12 (0.4) | |
HER-2 status | 0.2143 | |||
Positive | 58 (18.6) | 16 (20.3) | 692 (22.0) | |
Negative | 175 (56.1) | 51 (64.5) | 1753 (55.8) | |
Uncertain | 79 (25.3) | 12 (15.2) | 694 (22.1) | |
Ki-67 | 0.0056 | |||
Low | 105 (33.7) | 21 (26.6) | 798 (25.4) | |
High | 204 (65.4) | 58 (73.4) | 2328 (74.2) | |
Uncertain | 3 (0.9) | 0 (0) | 13 (0.4) | |
Subtype | 0.0704 | |||
ER−/PR−/HER-2− | 21 (6.7) | 5 (6.3) | 310 (9.9) | |
ER+/PR+/HER-2− | 154 (49.4) | 46 (58.2) | 1443 (46.0) | |
HER-2+ | 58 (18.6) | 16 (20.3) | 692 (22) | |
HER-2 uncertain | 79 (25.3) | 12 (15.2) | 694 (22.1) | |
